GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orphazyme AS (CHIX:ORPHAc) » Definitions » Equity-to-Asset

Orphazyme AS (CHIX:ORPHAC) Equity-to-Asset : 0.84 (As of Jun. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Orphazyme AS Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Orphazyme AS's Total Stockholders Equity for the quarter that ended in Jun. 2022 was kr78.21 Mil. Orphazyme AS's Total Assets for the quarter that ended in Jun. 2022 was kr93.59 Mil.

The historical rank and industry rank for Orphazyme AS's Equity-to-Asset or its related term are showing as below:

CHIX:ORPHAc's Equity-to-Asset is not ranked *
in the Biotechnology industry.
Industry Median: 0.67
* Ranked among companies with meaningful Equity-to-Asset only.

Orphazyme AS Equity-to-Asset Historical Data

The historical data trend for Orphazyme AS's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orphazyme AS Equity-to-Asset Chart

Orphazyme AS Annual Data
Trend Jun14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Equity-to-Asset
Get a 7-Day Free Trial 0.93 0.88 0.29 0.75 0.05

Orphazyme AS Quarterly Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.75 0.75 0.39 0.05 0.84

Competitive Comparison of Orphazyme AS's Equity-to-Asset

For the Biotechnology subindustry, Orphazyme AS's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orphazyme AS's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Orphazyme AS's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Orphazyme AS's Equity-to-Asset falls into.



Orphazyme AS Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Orphazyme AS's Equity to Asset Ratio for the fiscal year that ended in Dec. 2021 is calculated as

Equity to Asset (A: Dec. 2021 )=Total Stockholders Equity/Total Assets
=9.339/173.229
=0.05

Orphazyme AS's Equity to Asset Ratio for the quarter that ended in Jun. 2022 is calculated as

Equity to Asset (Q: Jun. 2022 )=Total Stockholders Equity/Total Assets
=78.205/93.589
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Orphazyme AS  (CHIX:ORPHAc) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Orphazyme AS Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Orphazyme AS's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Orphazyme AS (CHIX:ORPHAC) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Ole Maaloes Vej 3, Copenhagen, DNK, DK-2200
Orphazyme AS is a late-stage biopharmaceutical company engaged in the development and commercialization of novel therapeutics for the treatment of neurodegenerative rare diseases. The company's lead candidate, Arimoclomol, is in development for severe orphan diseases: Niemann-Pick disease Type C (NPC), Amyotrophic Lateral Sclerosis (ALS), and Inclusion Body Myositis (IBM).

Orphazyme AS (CHIX:ORPHAC) Headlines

No Headlines